PIK3CA mutations as prognostic factor in squamous cell lung carcinoma.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Lung Cancer

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.lungcan.2016.11.018PMID 28024696
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Regulation of PD-L1: a novel role of pro-survival signalling in cancer.

  2016cited by this paper
• PD-L1 is an independent prognostic predictor in gastric cancer of Western patients

  2016cited by this paper
• The PI3K/AKT Pathway as a Target for Cancer Treatment.

  2016cited by this paper
• Non-Small Cell Lung Cancer, Version 6.2015.

  2015cited by this paper
• Oncogenic mutations weaken the interactions that stabilize the p110α‐p85α heterodimer in phosphatidylinositol 3‐kinase α

  2015cited by this paper
• Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012

  2015cited by this paper
• Next-Generation Sequencing of Stage IV Squamous Cell Lung Cancers Reveals an Association of PI3K Aberrations and Evidence of Clonal Heterogeneity in Patients with Brain Metastases.

  2015cited by this paper
• Refining the treatment of NSCLC according to histological and molecular subtypes

  2015cited by this paper
• Induction of PD-L1 Expression by the EML4–ALK Oncoprotein and Downstream Signaling Pathways in Non–Small Cell Lung Cancer

  2015cited by this paper
• Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer

  2015cited by this paper
• A Randomized, Phase 2 Trial of Docetaxel with or without PX-866, an Irreversible Oral Phosphatidylinositol 3-Kinase Inhibitor, in Patients with Relapsed or Metastatic Non–Small-Cell Lung Cancer

  2014cited by this paper
• PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting

  2014cited by this paper
• Alterations of INPP4B, PIK3CA and pAkt of the PI3K pathway are associated with squamous cell carcinoma of the lung

  2014cited by this paper
• PIK3CA mutations in non-small cell lung cancer (NSCLC): Genetic heterogeneity, prognostic impact and incidence of prior malignancies

  2014cited by this paper
• First-in-Human Study of CH5132799, an Oral Class I PI3K Inhibitor, Studying Toxicity, Pharmacokinetics, and Pharmacodynamics, in Patients with Metastatic Cancer

  2014cited by this paper
• Programmed Cell Death 1 (PD-1) and Its Ligand (PD-L1) in Common Cancers and Their Correlation with Molecular Cancer Type

  2014cited by this paper
• Comprehensive molecular characterization of gastric adenocarcinoma

  2014cited by this paper
• Targeting the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway: an emerging treatment strategy for squamous cell lung carcinoma.

  2014cited by this paper
• Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers.

  2013cited by this paper
• PIK3CA gene mutation associated with poor prognosis of lung adenocarcinoma

  2013cited by this paper
• Development of PI3K/AKT/mTOR pathway inhibitors and their application in personalized therapy for non-small-cell lung cancer.

  2012cited by this paper
• The Activation of MAPK in Melanoma Cells Resistant to BRAF Inhibition Promotes PD-L1 Expression That Is Reversible by MEK and PI3K Inhibition

  2012cited by this paper
• Clarifying the Spectrum of Driver Oncogene Mutations in Biomarker-Verified Squamous Carcinoma of Lung: Lack of EGFR/KRAS and Presence of PIK3CA/AKT1 Mutations

  2012cited by this paper
• Comprehensive genomic characterization of squamous cell lung cancers

  2012cited by this paper
• Imaging , Diagnosis , Prognosis Prognostic Role of PIK 3 CA Mutation in Colorectal Cancer : Cohort Study and Literature Review

  2012cited by this paper
• Mosaic overgrowth with fibroadipose hyperplasia is caused by somatic activating mutations in PIK3CA

  2012cited by this paper
• Phosphoinositide 3-Kinase (PI3K) Pathway Alterations Are Associated with Histologic Subtypes and Are Predictive of Sensitivity to PI3K Inhibitors in Lung Cancer Preclinical Models

  2012cited by this paper
• A platform for rapid detection of multiple oncogenic mutations with relevance to targeted therapy in non-small-cell lung cancer.

  2011cited by this paper
• PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib

  2011cited by this paper
• Abstract 1041: Alterations of INPP4B, PIK3CA and pAkt of the PI3K pathway are associated with squamous cell carcinoma of the lung

  2011cited by this paper
• Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine

  2010cited by this paper
• Differential enhancement of breast cancer cell motility and metastasis by helical and kinase domain mutations of class IA phosphoinositide 3-kinase.

  2009cited by this paper
• PIK3CA Mutation Associates with Improved Outcome in Breast Cancer

  2009cited by this paper
• The PIK3CA gene is mutated with high frequency in human breast cancers

  2004cited by this paper
• High Frequency of Mutations of the PIK3CA Gene in Human Cancers

  2004cited by this paper
• Cigarette smoking and histologic type of lung cancer in men.

  1997cited by this paper
• Chinese a Nti鄄 Cancer a Ssociation

  year unknowncited by this paper

• Unraveling the molecular-pathological characteristics and cellular complexity of the tumor immune microenvironment in metastatic non-small cell lung cancer

  2025cites this paper
• Molecular characterization of EBV-associated primary pulmonary lymphoepithelial carcinoma by multiomics analysis

  2025cites this paper
• Clinicopathological and Molecular Insights into Primary Retroperitoneal Squamous Cell Carcinoma: HPV Association and Discovery of Recurrent PIK3CA E545K Mutation

  2025cites this paper
• Immune cell infiltration and drug sensitivity in PIK3CA-mutated esophageal squamous cell carcinoma: A TCGA database analysis.

  2024cites this paper
• Differential impact of intratumor heterogeneity (ITH) on survival outcomes in early-stage lung squamous and adenocarcinoma based on tumor mutational burden (TMB)

  2024cites this paper
• Highly consistency of PIK3CA mutation spectrum between circulating tumor DNA and paired tissue in lung cancer patients

  2024cites this paper
• Understanding PI3K/Akt/mTOR signaling in squamous cell carcinoma: mutated PIK3CA as an example

  2024influential citation
• Molecular Pathogenesis, Organ Metastasis, and Targeted Therapy for Non-Small-Cell Lung Cancer.

  2024cites this paper
• Single‐cell RNA sequencing reveals the mechanism of PI3K/AKT/mTOR signaling pathway activation in lung adenocarcinoma by KRAS mutation

  2024cites this paper
• Molecular profiling and prognostic biomarkers in chinese non-small cell lung cancer cohort

  2023influential citation
• Genomic profiling and metastatic risk in early-stage non–small cell lung cancer

  2023cites this paper
• A Review of Biomarkers and Their Clinical Impact in Resected Early-Stage Non-Small-Cell Lung Cancer

  2023cites this paper
• Gene‐level dissection of chromosome 3q locus amplification in squamous cell carcinoma of the lung using the nCounter assay

  2023cites this paper
• “Evaluation of ROS1 expression and rearrangements in a large cohort of early-stage lung cancer”

  2023cites this paper
• Identifying druggable targets from active constituents of Azadirachta indica A. Juss. for non-small cell lung cancer using network pharmacology and validation through molecular docking.

  2023cites this paper
• A Mechanism Exploration for the Yi-Fei-San-Jie Formula against Non-Small-Cell Lung Cancer Based on UPLC-MS/MS, Network Pharmacology, and In Silico Verification

  2023cites this paper
• The PI3K/Akt/mTOR pathway in lung cancer; oncogenic alterations, therapeutic opportunities, challenges, and a glance at the application of nanoparticles

  2022cites this paper
• Mutations in the TTN Gene are a Prognostic Factor for Patients with Lung Squamous Cell Carcinomas

  2022cites this paper
• Narrative review of emerging roles for AKT-mTOR signaling in cancer radioimmunotherapy

  2021cites this paper
• Molecular characteristics of primary pulmonary lymphoepithelioma-like carcinoma based on integrated genomic analyses

  2021cites this paper
• Circ_0000020 elevates the expression of PIK3CA and facilitates the malignant phenotypes of glioma cells via targeting miR-142-5p

  2021cites this paper
• Immune subgroup analysis for non-small cell lung cancer may be a good choice for evaluating therapeutic efficacy and prognosis

  2021cites this paper
• Analysis of EGFR, KRAS, and PIK3CA gene mutation rates and clinical distribution in patients with different types of lung cancer

  2021cites this paper
• Molecular Pathology of Primary Non-small Cell Lung Cancer.

  2020cites this paper
• The Mechanisms of PD-L1 Regulation in Non-Small-Cell Lung Cancer (NSCLC): Which Are the Involved Players?

  2020cites this paper
• The Extrinsic and Intrinsic Roles of PD-L1 and Its Receptor PD-1: Implications for Immunotherapy Treatment

  2020cites this paper
• Clinical Significance of PIK3CA Gene in Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis

  2020cites this paper
• Genomic Applications in Pathology

  2019cites this paper
• Recent Findings in the Regulation of Programmed Death Ligand 1 Expression

  2019cites this paper
• Prognostic value of KRAS/TP53/PIK3CA in non-small cell lung cancer

  2019cites this paper
• Aggregate analysis based on TCGA: TTN missense mutation correlates with favorable prognosis in lung squamous cell carcinoma

  2019cites this paper
• The prognostic impact of obstructive lung disease on survival of never smokers with resected non-small-cell lung cancer: a comparison with smokers.

  2019cites this paper
• A subtype of oral, laryngeal, esophageal, and lung, squamous cell carcinoma with high levels of TrkB-T1 neurotrophin receptor mRNA

  2019cites this paper
• Phosphatidylinositol-3-Kinase Mutations Are Associated With Increased Local Failure in Brain Metastases Treated With Radiation.

  2018cites this paper
• Genomic Applications in Pulmonary Malignancies

  2018cites this paper
• PIK3CA mutation is associated with increased local failure in lung stereotactic body radiation therapy (SBRT)

  2017cites this paper
• Advanced squamous lung cancer: therapeutic options, future directions, unmet needs and results of a monocentric survey.

  2017cites this paper